Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/26412456/ below:

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Clinical Trial

Affiliations

• ¹ From the Fox Chase Cancer Center, Philadelphia (H.B.); Hospital Universitario Virgen del Rocio, Seville (L.P.-A.), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Hospital de Madrid, Norte Sanchinarro, Madrid (E.H.) - all in Spain; Vanderbilt-Ingram Cancer Center (L.H.), and Sarah Cannon Research Institute and Tennessee Oncology (D.R.S.) - both in Nashville; Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) and Robert-Bosch-Krankenhaus Stuttgart, Gerlingen (M.K.) - both in Germany; Duke University Medical Center, Durham, NC (N.E.R.); University of Washington, Seattle (L.Q.C.); University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.), Centre Léon Bérard, Lyon (J.F.), and Centre Hospitalier Universitaire de Rennes, Rennes (H.L.) - all in France; Instituto Nacional de Cancerologia, Mexico City (O.A.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Forlì-Cesena (M.A.B.), and Ospedale di Perugia, Perugia (L.C.) - both in Italy; N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); University of Texas Southwestern Medical Center, Dallas (D.E.G.); Yale Comprehensive Cancer Center, New Haven, CT (S.N.G.); Memorial Sloan Kettering Cancer Center, New York (C.M.R., N.R.); University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.J.A.); Bristol-Myers Squibb, Princeton, NJ (C.D., C.T.H., F.G.F.); and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.R.B.).

• PMID: 26412456
• PMCID: PMC5705936
• DOI: 10.1056/NEJMoa1507643

Item in Clipboard

Clinical Trial

Hossein Borghaei et al. N Engl J Med. 2015.

• ¹ From the Fox Chase Cancer Center, Philadelphia (H.B.); Hospital Universitario Virgen del Rocio, Seville (L.P.-A.), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Hospital de Madrid, Norte Sanchinarro, Madrid (E.H.) - all in Spain; Vanderbilt-Ingram Cancer Center (L.H.), and Sarah Cannon Research Institute and Tennessee Oncology (D.R.S.) - both in Nashville; Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) and Robert-Bosch-Krankenhaus Stuttgart, Gerlingen (M.K.) - both in Germany; Duke University Medical Center, Durham, NC (N.E.R.); University of Washington, Seattle (L.Q.C.); University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.), Centre Léon Bérard, Lyon (J.F.), and Centre Hospitalier Universitaire de Rennes, Rennes (H.L.) - all in France; Instituto Nacional de Cancerologia, Mexico City (O.A.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Forlì-Cesena (M.A.B.), and Ospedale di Perugia, Perugia (L.C.) - both in Italy; N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); University of Texas Southwestern Medical Center, Dallas (D.E.G.); Yale Comprehensive Cancer Center, New Haven, CT (S.N.G.); Memorial Sloan Kettering Cancer Center, New York (C.M.R., N.R.); University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.J.A.); Bristol-Myers Squibb, Princeton, NJ (C.D., C.T.H., F.G.F.); and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.R.B.).

• PMID: 26412456
• PMCID: PMC5705936
• DOI: 10.1056/NEJMoa1507643

Item in Clipboard

Background: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.

Methods: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival.

Results: Overall survival was longer with nivolumab than with docetaxel. The median overall survival was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 months (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P=0.002). At 1 year, the overall survival rate was 51% (95% CI, 45 to 56) with nivolumab versus 39% (95% CI, 33 to 45) with docetaxel. With additional follow-up, the overall survival rate at 18 months was 39% (95% CI, 34 to 45) with nivolumab versus 23% (95% CI, 19 to 28) with docetaxel. The response rate was 19% with nivolumab versus 12% with docetaxel (P=0.02). Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively), the rate of progression-free survival at 1 year was higher with nivolumab than with docetaxel (19% and 8%, respectively). Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1%, ≥5%, and ≥10%) of the PD-1 ligand. Treatment-related adverse events of grade 3 or 4 were reported in 10% of the patients in the nivolumab group, as compared with 54% of those in the docetaxel group.

Conclusions: Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).

PubMed Disclaimer

Data are…

Data are based on a March 18, 2015 database lock. (A) Kaplan-Meier plot of overall survival. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. (B) Treatment effect on overall survival in pre-defined subsets. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). HR was not computed for other subsets with less than 10 patients per treatment group. (C) Characteristics of response and progression as assessed per investigator. Ongoing response at last tumor assessment before censoring. Bar indicates progression-free survival. (D) Kaplan-Meier plot of progression-free survival. Progression-free survival was defined as the time from randomization to date of first documented tumor progression, death or last evaluable tumor assessment (censoring date). All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; EGFR = epidermal growth factor receptor; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors.

Data are…

Data are based on a March 18, 2015 database lock. (A) Kaplan-Meier plot of overall survival. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. (B) Treatment effect on overall survival in pre-defined subsets. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). HR was not computed for other subsets with less than 10 patients per treatment group. (C) Characteristics of response and progression as assessed per investigator. Ongoing response at last tumor assessment before censoring. Bar indicates progression-free survival. (D) Kaplan-Meier plot of progression-free survival. Progression-free survival was defined as the time from randomization to date of first documented tumor progression, death or last evaluable tumor assessment (censoring date). All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; EGFR = epidermal growth factor receptor; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors.

Data are…

Data are based on a March 18, 2015 database lock. (A) Kaplan-Meier plot of overall survival. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. (B) Treatment effect on overall survival in pre-defined subsets. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). HR was not computed for other subsets with less than 10 patients per treatment group. (C) Characteristics of response and progression as assessed per investigator. Ongoing response at last tumor assessment before censoring. Bar indicates progression-free survival. (D) Kaplan-Meier plot of progression-free survival. Progression-free survival was defined as the time from randomization to date of first documented tumor progression, death or last evaluable tumor assessment (censoring date). All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; EGFR = epidermal growth factor receptor; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors.

Data are…

Data are based on a March 18, 2015 database lock. (A) Kaplan-Meier plot of overall survival. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. (B) Treatment effect on overall survival in pre-defined subsets. All randomized patients (nivolumab, n = 292; docetaxel, n = 290). HR was not computed for other subsets with less than 10 patients per treatment group. (C) Characteristics of response and progression as assessed per investigator. Ongoing response at last tumor assessment before censoring. Bar indicates progression-free survival. (D) Kaplan-Meier plot of progression-free survival. Progression-free survival was defined as the time from randomization to date of first documented tumor progression, death or last evaluable tumor assessment (censoring date). All randomized patients (nivolumab, n = 292; docetaxel, n = 290). Symbols represent censored observations. CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; EGFR = epidermal growth factor receptor; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors.

• Nivolumab--an effective second-line treatment for NSCLC.

  Romero D. Romero D. Nat Rev Clin Oncol. 2015 Dec;12(12):685. doi: 10.1038/nrclinonc.2015.184. Epub 2015 Oct 20. Nat Rev Clin Oncol. 2015. PMID: 26483299 No abstract available.

• Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

  Borghaei H, Brahmer J. Borghaei H, et al. N Engl J Med. 2016 Feb 4;374(5):493-4. doi: 10.1056/NEJMc1514790. N Engl J Med. 2016. PMID: 26840144 No abstract available.

• Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

  Hasegawa T, Uno H, Wei LJ. Hasegawa T, et al. N Engl J Med. 2016 Feb 4;374(5):492-3. doi: 10.1056/NEJMc1514790. N Engl J Med. 2016. PMID: 26840145 No abstract available.

• Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

  Gyawali B, Ota A, Ando Y. Gyawali B, et al. N Engl J Med. 2016 Feb 4;374(5):493. doi: 10.1056/NEJMc1514790. N Engl J Med. 2016. PMID: 26840146 No abstract available.

• The quest to extend the reach of checkpoint inhibitors in lung cancer.

  Weintraub K. Weintraub K. Nature. 2017 Dec 21;552(7685):S62-S63. doi: 10.1038/d41586-017-08700-9. Nature. 2017. PMID: 29293220 No abstract available.

• Statistical Interpretation and Comparison of Waterfall Plots.

  Huang M, Chen C, Sun LZ. Huang M, et al. JCO Clin Cancer Inform. 2023 Sep;7:e2300132. doi: 10.1200/CCI.23.00132. JCO Clin Cancer Inform. 2023. PMID: 37906725

• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Brahmer J, et al. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31. N Engl J Med. 2015. PMID: 26028407 Free PMC article. Clinical Trial.

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

  Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Horn L, et al. J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12. J Clin Oncol. 2017. PMID: 29023213 Free PMC article. Clinical Trial.

• FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.

  Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R. Kazandjian D, et al. Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16. Oncologist. 2016. PMID: 26984449 Free PMC article. Clinical Trial.

• A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.

  Wang C, Yu X, Wang W. Wang C, et al. Medicine (Baltimore). 2016 Dec;95(52):e5539. doi: 10.1097/MD.0000000000005539. Medicine (Baltimore). 2016. PMID: 28033249 Free PMC article. Review.

• Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

  Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Melosky B, et al. J Clin Oncol. 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884577 Review.

• Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

  Cole M, Anastasiou P, Lee C, Yu X, de Castro A, Roelink J, Moore C, Mugarza E, Jones M, Valand K, Rana S, Colliver E, Angelova M, Enfield KSS, Magness A, Mullokandov A, Kelly G, de Gruijl TD, Molina-Arcas M, Swanton C, Downward J, van Maldegem F. Cole M, et al. Sci Adv. 2024 Nov;10(44):eadl6464. doi: 10.1126/sciadv.adl6464. Epub 2024 Nov 1. Sci Adv. 2024. PMID: 39485838 Free PMC article.

• Identification of combinations of somatic mutations that predict cancer survival and immunotherapy benefit.

  Gussow AB, Koonin EV, Auslander N. Gussow AB, et al. NAR Cancer. 2021 May 17;3(2):zcab017. doi: 10.1093/narcan/zcab017. eCollection 2021 Jun. NAR Cancer. 2021. PMID: 34027407 Free PMC article.

• Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer.

  Chen B, Yang M, Li K, Li J, Xu L, Xu F, Xu Y, Ren D, Zhang J, Liu L. Chen B, et al. Oncol Lett. 2021 Jul;22(1):540. doi: 10.3892/ol.2021.12801. Epub 2021 May 19. Oncol Lett. 2021. PMID: 34084219 Free PMC article.

• Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China.

  Mizuno T, Katsuya Y, Sato J, Koyama T, Shimizu T, Yamamoto N. Mizuno T, et al. Front Oncol. 2022 Aug 26;12:925938. doi: 10.3389/fonc.2022.925938. eCollection 2022. Front Oncol. 2022. PMID: 36091105 Free PMC article. Review.

• Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis.

  Pasello G, Pavan A, De Nuzzo M, Frega S, Ferro A, Dal Maso A, Bonanno L, Guarneri V, Girardi F. Pasello G, et al. Front Oncol. 2024 Jul 9;14:1415470. doi: 10.3389/fonc.2024.1415470. eCollection 2024. Front Oncol. 2024. PMID: 39045561 Free PMC article.

1. 1. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin oncol. 2000;18:2354–62. - PubMed
2. 1. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103. - PubMed
3. 1. Taxotere (docetaxel) US Prescribing Information. 2010 May; Accessed March 23, 2015, at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf.
4. 1. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97. - PubMed
5. 1. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981–88. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3